Archive for December 2004
Mechanistic Disease Progression Model for Type 2 Diabetes Mellitus and Pioglitazone Treatment Effects
Winter W.d., Post T., Jongh J.d., Urquhardt R., Moules I., Eckland D. and Danhof M.A., Mechanistic Disease Progression Model for Type 2 Diabetes Mellitus and Pioglitazone Treatment Effects. PAGE.(2004). [Link to publication]
Read MoreReversal of rocuronium-induced neuromuscular block by cyclodextin ORG 25969
Ploeger B., Houwing N., Bom A., Zollinger D. and Danhof M., Reversal of rocuronium-induced neuromuscular block by cyclodextin ORG 25969: model development and validation. PAGE.(2004). [Link to publication]
Read MoreDevelopment of a mechanism-based PK-PD model of the reversal of rocuronium-induced neuromuscular block by ORG25969
Ruigt G.S., Ploeger B., Danhof M., Bom A., Houwing N. and Iersel M.P.v., Development of a mechanism-based PK-PD model of the reversal of rocuronium-induced neuromuscular block by ORG25969. IARS.(2004). [Link to publication]
Read MoreDisease Progression Analysis for Type 2 Diabetes Mellitus
Winter W.d., Post T.M., Jongh J.d., Moules I., Urquhart R., Eckland D. and Danhof M., Disease Progression Analysis for Type 2 Diabetes Mellitus: Bridging Therapeutic Intervention and Disease Outcome. Figon.(2004).
Read MoreTowards a Mechanistic Disease Progression Model for Type 2 Diabetes Mellitus
Winter W.d., Jongh J.d., Eckland D. and Danhof M., Towards a Mechanistic Disease Progression Model for Type 2 Diabetes Mellitus. ASCPT.(2004).
Read MorePK-PD modelling of reversal of neuromuscular by a chemically optimised cyclodextrin
Ploeger B., Ruigt G.S., Bom A., Houwing N., Iersel M.P.v. and Danhof M., PK-PD modelling of reversal of neuromuscular by a chemically optimised cyclodextrin. ASCPT.(2004).
Read MoreAbsorption model based on transport physics theory applied to Paracetamol
Freijer J.I., Post T.M., Ploeger B.A., Jongh J.d. and Danhof M., Absorption model based on transport physics theory applied to Paracetamol. ASCPT.(2004).
Read MoreMechanistic Disease Progression Analysis Indicates that Pioglitazone Prevents the Progression of T2DM
Winter W.d., Jongh J.d., Moules I., Urquhart R., Eckland D. and Danhof M., Mechanistic Disease Progression Analysis Indicates that Pioglitazone Prevents the Progression of T2DM. ADA.(2004).
Read MoreApplication of Population Pharmacokinetic Analysis for Quantification of in vivo Binding Properties in the Rat Brain
Liefaard C.L., Ploeger B.A., Molthoff C.F.M., Boellaard R., Lammertsma A.A., Danhof M. and Voskuyl R.A., Application of Population Pharmacokinetic Analysis for Quantification of in vivo Binding Properties in the Rat Brain by Positron Emission Tomography. PAGE.(2004). [Link to publication]
Read MoreMechanistic Disease Progression Analysis
Winter W.d., Jongh J.d., Urquhart R., Moules I., Eckland D. and Danhof M., Mechanistic Disease Progression Analysis Indicates that Pioglitazone Impedes the Progression of Type 2 Diabetes Mellitus (T2DM) in Combination Therapy with Sulphonylurea and Metformin. EASD.(2004).
Read More